09 February 2025 : Clinical Research
Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer
Yonca Yılmaz Ürün
ABF 1, İsmail Beypınar CDE 2*
DOI: 10.12659/MSM.947202
Med Sci Monit 2025; 31:e947202
Table 2 Chemotherapy regimens and chemotherapy adverse effects.
| Chemotherapy regimens | Percentage | Adverse events | Percentage |
|---|---|---|---|
| Cisplatin+5-FU | 22.1 | Grade 3–4 anemia | 6.7 |
| Carboplatin-paclitaxel | 25.7 | Grade 3–4 neutropenia | 19.8 |
| 5-FU | 1.8 | Grade 3–4 thrombocytopenia | 2.9 |
| Paclitaxel | 4.4 | Febrile neutropenia | 2.9 |
| mDCF | 27.4 | Grade 3–4 mucositis | 2.9 |
| FOLFOX | 9.7 | ||
| FOLFIRI | 6.2 | ||
| FLOT | 0.9 | ||
| Cisplatin-etoposide | 1.8 |